Loading
companiesCompany
Rakuten Medical
Rakuten Medical is a United States-based biotechnology company running 3 late-stage cancer trials in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma.
Also called: Rakuten Medical, Inc.
Overview
Rakuten Medical, based in San Diego, the United States, is a biotechnology company. Rakuten Medical is a biotechnology company creating and bringing to market drugs and devices to treat cancers based on its Alluminox platform of photoimmunotherapy. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma. The largest, NCT06699212 (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases), plans to enrol 412 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
San Diego, US
Scorecard
All companies#288of 1244 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
1 approved, 0 in phase 3, 0 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
2010
ApprovedPhotoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye)
Cetuximab sarotalocan · Akalux
Cetuximab sarotalocan is an EGFR antibody carrying a light-activated dye: after infusion, a red laser is shone on the tumour and the cells burst. It has been approved in Japan since 2020.
Similar pages
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma.
- TechnologyPhotoimmunotherapy & photodynamic therapy
Shares Cetuximab sarotalocan, Photodynamic therapy lasers and light sources, Head and neck squamous cell carcinoma.
- IdeaPhotoimmunotherapy as an in situ vaccine with PD-1 blockade
Shares Cetuximab sarotalocan, A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of , Head and neck squamous cell carcinoma.
- CompanyGalderma
Shares Photodynamic therapy lasers and light sources, Cutaneous squamous cell carcinoma.
- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma.
- TechnologySuperficial and orthovoltage radiotherapy for skin cancer
Shares Photodynamic therapy lasers and light sources, Cutaneous squamous cell carcinoma.
- TreatmentTemoporfin
Shares Photodynamic therapy lasers and light sources, Head and neck squamous cell carcinoma.
- TrialA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma.
cancers
technologies
drugs
ApprovedPhotoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye)
Cetuximab sarotalocan · Akalux
trials
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy